Global Axillary Hyperhidrosis (AHH) Epidemiology 2023-2032: Emerging Therapies and Growing Market

DUBLIN, July 28, 2023 /PRNewswire/ -- The Axillary Hyperhidrosis (AHH): Global Industry Insights, Epidemiology, and Forecast to 2032 report has been added to ResearchAndMarkets.com's offering.

The market for axillary hyperhidrosis (AHH) is experiencing significant growth and is projected to continue expanding until 2032. The United States holds the largest market size, reaching approximately USD 500 million in 2022.

This report report provides a comprehensive understanding of the epidemiology and market trends of AHH in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. The report covers current treatment practices, emerging drugs, market size, and forecasts from 2019 to 2032. It also highlights the unmet medical needs and potential opportunities in the market.

AHH is a bothersome condition that can disrupt daily activities and lead to embarrassment and isolation. The psychological and physical health, as well as occupational life, of those affected by AHH are significantly affected. From the discomfort of sweat running down the sides to the embarrassment of obvious sweat stains, the uncontrollable underarm sweating can feel like it's ruining one's life.

Genetic factors play a role in the development of AHH. The main genes associated with the condition are butyrylcholinesterase (BCHe) and Cholinergic Receptor Nicotinic Alpha-7 subunit (CHRNA7). These genes influence the production and activity of acetylcholine, a neurotransmitter. Mutations in these genes can lead to abnormal neurotransmitter production, resulting in AHH.

Although there is currently no cure for AHH, various treatment options are available to manage the condition. The recommended first-line treatment is topical antiperspirants. These are the least expensive option but are not as effective in the long term and may cause skin irritations. For patients who do not respond well to topical treatments, botulinum toxin A injections are recommended as the second-line treatment.

The market for AHH also sees the emergence of new therapies that have the potential to positively impact its size. One such therapy is ECCLOCK, developed by Botanix Pharmaceuticals. These innovative treatments are expected to drive the growth of the AHH market.

In conclusion, the market for axillary hyperhidrosis (AHH) is growing rapidly, with the United States leading in market size. Genetic factors play a role in AHH, and although there is no cure, various treatment options are available. The emergence of new therapies, such as ECCLOCK, offers potential opportunities for market growth. The report provides valuable insights for those involved in market research for AHH.

Key Highlights

• In 2022, the market size of AHH was highest in the US, accounting for approximately USD 500 million, which is further expected to increase by 2032.
• The main genes linked to hyperhidrosis are butyrylcholinesterase (BCHe) and Cholinergic Receptor Nicotinic Alpha-7 subunit (CHRNA7). Both genes influence the activity and production of acetylcholine, and mutations of these genes can lead to abnormal neurotransmitter production
• Currently, there is no cure for Axillary Hyperhidrosis (AH); many products, medications, and home remedies exist to help minimize underarm sweat. Topical antiperspirant treatments are the recommended first-line treatment being the least expensive. However, they are not as effective as the other treatments in the long term and cause skin irritations. Botulinum toxin A injections are the recommended second-line treatment for patients who fail topical treatments.
• As per the International Hyperhidrosis Society Clinical Guidelines for the Treatment of Primary Focal Axillary Hyperhidrosis, the general recommendation is to try more conservative therapy before resorting to invasive treatment. For many patients, treatment will begin with topical antiperspirants starting with over-the-counter "clinical strength" products (active ingredient often zirconium salts) and then prescription products.
• Oral systemic medications, including anticholinergics (glycopyrrolate, oxybutynin, and propantheline), propranolol, clonidine, and diltiazem may be used to treat primary axillary hyperhidrosis but require patient education regarding potential side effects (such as dry mouth, blurred vision, urinary retention, tachycardia, and constipation).
• QBREXZA (glycopyrronium) was approved by the US FDA in 2018. Recently in 2022, Journey Medical Corporation received notice from its exclusive licensing partner in Japan, Maruho Co., Ltd. ("Maruho"), that Japan's Ministry of Health, Labor and Welfare ("MHLW") approved RAPIFORT Wipes 2.5% (glycopyrronium tosylate hydrate) to treat primary axillary hyperhidrosis.
• Research on AHH still has a lot of opportunity for improvement as it is often underdiagnosed and understudied as a disease. QBREXZA (glycopyrronium) is US FDA approved, but its safety in children below 9 years of age is unknown. Moreover, it has various side effects, including blurred vision and dehydration.
• The emerging therapies in the market for AHH include ECCLOCK (Botanix Pharmaceuticals) and others that might create a significant positive shift in the AHH market size.

Key Topics Covered

1. Key Insights
2. Report Introduction
3. Axillary Hyperhidrosis Market Overview at a Glance
4. Executive Summary of Axillary Hyperhidrosis
5. Disease Background and Overview
6. Treatment
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Drugs
12. AHH: The 7MM Market Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/6fwyih

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets